Abstract
BackgroundGastrointestinal reflux disease (GERD) is a common disorder that negatively impacts health-related quality of life (HRQL) and work productivity. Many patients have only a partial response to proton pump inhibitor (PPI) therapy and continue to experience GERD symptoms despite optimized treatment. This observational study aimed to provide information on symptoms, HRQL, resource usage, costs and treatment pathways associated with partial response to PPI therapy in French patients with GERD.MethodsPatients with partial response to PPI therapy, defined as persistent GERD symptoms ≥3 days/week despite optimized treatment with a PPI, were recruited for this 12-month observational study. GERD symptoms, HRQL, work productivity and resource use were assessed by patient surveys. Costs were calculated based on lost work productivity and resource use.ResultsThe patient population (n=262; mean age, 54 years; 40% men) carried a significant symptom burden, with 98% of patients having moderate-to-severe GERD symptoms and 65% of patients experiencing daily symptoms at baseline. HRQL and work productivity were significantly impaired, with a greater degree of impairment in patients with higher symptom burden. The mean total cost per patient over the 12-month follow-up period was €5237, of which €4674 (89%) was due to lost work productivity.ConclusionsPartial response to PPI therapy for GERD is associated with a high symptom burden, significant impairment of HRQL and work productivity, and substantial GERD-related costs.
Highlights
Gastrointestinal reflux disease (GERD) is a common disorder that negatively impacts health-related quality of life (HRQL) and work productivity
Patients experienced an approximate 30% reduction in work productivity, and a 41% reduction in productivity during daily activities, with the degree of productivity and HRQL impairment being positively correlated with the severity and frequency of GERD symptoms despite optimized pump inhibitor (PPI) therapy [5]
The REMAIN (Partial Response to PPI treatment: the Cost to Society and the Burden to the Patient) France study aimed to provide information on the treatment pathways, resource utilization, costs, symptoms and HRQL in European patients with GERD who were newly identified as partial responders to optimized PPI therapy
Summary
Gastrointestinal reflux disease (GERD) is a common disorder that negatively impacts health-related quality of life (HRQL) and work productivity. Many patients have only a partial response to proton pump inhibitor (PPI) therapy and continue to experience GERD symptoms despite optimized treatment. This observational study aimed to provide information on symptoms, HRQL, resource usage, costs and treatment pathways associated with partial response to PPI therapy in French patients with GERD. Gastroesophageal reflux disease (GERD) is a common disorder, the predominant symptoms of heartburn and/ or regurgitation affecting approximately 10–20% of the adult population in the Western world [1]. 17–32% of patients have only a partial response and continue to experience GERD symptoms despite optimized therapy with a PPI [4]. There are little data on disease burden, resource use, costs and treatment pathways in this patient population in Europe
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
